Servicio de Nefrologia, Fundación para la Investigación Biomédica del Hospital Universitario La Paz, Madrid, Spain.
PLoS One. 2010 Jan 29;5(1):e8955. doi: 10.1371/journal.pone.0008955.
TWEAK is a member of the TNF superfamily of cytokines that contribute to kidney tubulointerstitial injury. It has previously been reported that TWEAK induces transient nuclear translocation of RelA and expression of RelA-dependent cytokines in renal tubular cells. Additionally, TWEAK induced long-lasting NFkappaB activation suggestive of engagement of the non-canonical NFkappaB pathway. We now explore TWEAK-induced activation of NFkappaB2 and RelB, as well as expression of CCL21, a T-cell chemotactic factor, in cultured murine tubular epithelial cells and in healthy kidneys in vivo. In cultured tubular cells, TWEAK and TNFalpha activated different DNA-binding NFkappaB complexes. TWEAK-induced sustained NFkappaB activation was associated with NFkappaB2 p100 processing to p52 via proteasome and nuclear translocation and DNA-binding of p52 and RelB. TWEAK, but not TNFalpha used as control), induced a delayed increase in CCL21a mRNA (3.5+/-1.22-fold over control) and CCL21 protein (2.5+/-0.8-fold over control), which was prevented by inhibition of the proteasome, or siRNA targeting of NIK or RelB, but not by RelA inhibition with parthenolide. A second NFkappaB2-dependent chemokine, CCL19, was upregulates by TWEAK, but not by TNFalpha. However, both cytokines promoted chemokine RANTES expression (3-fold mRNA at 24 h). In vivo, TWEAK induced nuclear NFkappaB2 and RelB translocation and CCL21a mRNA (1.5+/-0.3-fold over control) and CCL21 protein (1.6+/-0.5-fold over control) expression in normal kidney. Increased tubular nuclear RelB and tubular CCL21 expression in acute kidney injury were decreased by neutralization (2+/-0.9 vs 1.3+/-0.6-fold over healthy control) or deficiency of TWEAK (2+/-0.9 vs 0.8+/-0.6-fold over healthy control). Moreover, anti-TWEAK treatment prevented the recruitment of T cells to the kidney in this model (4.1+/-1.4 vs 1.8+/-1-fold over healthy control). Our results thus identify TWEAK as a regulator of non-canonical NFkappaB activation and CCL21 expression in tubular cells thus promoting lymphocyte recruitment to the kidney during acute injury.
TWEAK 是 TNF 细胞因子超家族的一员,可导致肾小管间质损伤。先前的研究表明,TWEAK 可诱导肾近端小管细胞中 RelA 的瞬时核易位和 RelA 依赖性细胞因子的表达。此外,TWEAK 诱导的 NFkappaB 持续激活提示非经典 NFkappaB 途径的参与。我们现在探讨 TWEAK 在培养的鼠肾小管上皮细胞和体内健康肾脏中诱导 NFkappaB2 和 RelB 的激活以及趋化因子 CCL21 的表达,CCL21 是一种 T 细胞趋化因子。在培养的肾小管细胞中,TWEAK 和 TNFalpha 激活了不同的 DNA 结合 NFkappaB 复合物。TWEAK 诱导的持续 NFkappaB 激活与 NFkappaB2 p100 通过蛋白酶体加工为 p52 以及 p52 和 RelB 的核易位和 DNA 结合有关。TWEAK(但 TNFalpha 用作对照)诱导 CCL21a mRNA(对照的 3.5+/-1.22 倍)和 CCL21 蛋白(对照的 2.5+/-0.8 倍)的延迟增加,该增加可被蛋白酶体抑制剂、针对 NIK 或 RelB 的 siRNA 或 RelA 抑制剂(部分白屈菜碱)所预防。第二种 NFkappaB2 依赖性趋化因子 CCL19 也可被 TWEAK 上调,但不能被 TNFalpha 上调。然而,两种细胞因子均促进趋化因子 RANTES 的表达(24 小时时 mRNA 增加 3 倍)。在体内,TWEAK 诱导正常肾脏中 NFkappaB2 和 RelB 的核易位以及 CCL21a mRNA(对照的 1.5+/-0.3 倍)和 CCL21 蛋白(对照的 1.6+/-0.5 倍)的表达。急性肾损伤中肾小管核 RelB 和肾小管 CCL21 表达的增加可通过中和(对照的 2+/-0.9 倍)或 TWEAK 缺乏(对照的 2+/-0.9 倍)来减少。此外,抗 TWEAK 治疗可防止该模型中 T 细胞募集到肾脏(对照的 4.1+/-1.4 倍)。因此,我们的结果表明 TWEAK 是肾小管细胞中非经典 NFkappaB 激活和 CCL21 表达的调节剂,从而在急性损伤期间促进淋巴细胞募集到肾脏。